ATE506059T1 - Therapie zur behandlung der überaktiven blase - Google Patents

Therapie zur behandlung der überaktiven blase

Info

Publication number
ATE506059T1
ATE506059T1 AT06813885T AT06813885T ATE506059T1 AT E506059 T1 ATE506059 T1 AT E506059T1 AT 06813885 T AT06813885 T AT 06813885T AT 06813885 T AT06813885 T AT 06813885T AT E506059 T1 ATE506059 T1 AT E506059T1
Authority
AT
Austria
Prior art keywords
overactive bladder
therapy
treat overactive
disclosed
pharmaceutically acceptable
Prior art date
Application number
AT06813885T
Other languages
English (en)
Inventor
Mehdi Paborji
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Application granted granted Critical
Publication of ATE506059T1 publication Critical patent/ATE506059T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
AT06813885T 2005-09-02 2006-08-28 Therapie zur behandlung der überaktiven blase ATE506059T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71415005P 2005-09-02 2005-09-02
PCT/US2006/033671 WO2007027675A1 (en) 2005-09-02 2006-08-28 Therapy for the treatment of disease

Publications (1)

Publication Number Publication Date
ATE506059T1 true ATE506059T1 (de) 2011-05-15

Family

ID=37502599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06813885T ATE506059T1 (de) 2005-09-02 2006-08-28 Therapie zur behandlung der überaktiven blase

Country Status (19)

Country Link
US (6) US7678821B2 (de)
EP (1) EP1933833B8 (de)
JP (1) JP5312027B2 (de)
KR (1) KR101054248B1 (de)
CN (2) CN103142586A (de)
AT (1) ATE506059T1 (de)
AU (1) AU2006284940B2 (de)
BR (1) BRPI0615432A2 (de)
CA (1) CA2619565C (de)
DE (1) DE602006021444D1 (de)
DK (1) DK1933833T3 (de)
ES (1) ES2365161T3 (de)
IL (1) IL189546A (de)
NZ (1) NZ565840A (de)
PL (1) PL1933833T3 (de)
PT (1) PT1933833E (de)
RU (1) RU2435610C2 (de)
WO (1) WO2007027675A1 (de)
ZA (1) ZA200802811B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200802811B (en) * 2005-09-02 2009-09-30 Theravida Inc Therapy for the treatment of disease
JP5637551B2 (ja) * 2005-12-28 2014-12-10 キッセイ薬品工業株式会社 唾液腺障害の治療用医薬
US20100297225A1 (en) * 2007-12-20 2010-11-25 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PL3061821T3 (pl) * 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
MX2012011395A (es) * 2010-04-01 2013-02-26 Theravida Inc Metodos de mejoramiento de la calidad del sueño.
CN102325467B (zh) * 2010-05-12 2013-10-09 沈宝美 根据体质不同的用于改善便秘的天然食品组合物
TW201212939A (en) * 2010-06-22 2012-04-01 Anu Mahashabde Intravaginal devices comprising anticholinergic agents, and methods of making thereof
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR101932714B1 (ko) * 2010-09-28 2018-12-26 삼성전자주식회사 소셜 그룹 생성 및 연결 방법, 그 방법을 수행할 수 있는 유저 디바이스, 서버 및 저장 매체
AU2012253669A1 (en) * 2011-05-10 2013-11-28 Theravida, Inc. Combinations of trospium and salivary stimulants for the treatment of overactive bladder
WO2012154892A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
US20120289564A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
CA2835277A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
US20120289561A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20120289563A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder
US20120289562A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
NZ718163A (en) * 2012-03-19 2017-09-29 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20150013657A (ko) 2012-05-01 2015-02-05 테라비다, 인코포레이티드 과민성 방광의 치료 방법
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US20170361091A1 (en) 2014-12-23 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot
CA2978201A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists
EP3405191A4 (de) * 2016-01-20 2019-09-04 TheraVida, Inc. Verfahren und zusammensetzungen zur behandlung von hyperhidrose
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼の状態の治療のためのピロカルピン塩酸塩の使用
EA202190356A1 (ru) 2018-09-28 2021-08-13 Каруна Терапеутикс, Инк. Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов
EP3967311A1 (de) 2020-09-11 2022-03-16 Astellas Pharma Inc. Verbindungen zur verwendung bei der behandlung von mundtrockenheit
US11564909B2 (en) 2020-11-30 2023-01-31 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CZ299283B6 (cs) 1997-12-22 2008-06-04 Euro-Celtique, S. A. Léková forma pro perorální podání
EP1041988A4 (de) 1997-12-22 2002-03-13 Euro Celtique Sa Verfahren zur vorbeugung von missbrauch von opioid-dosis-formen
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
EP1258253A1 (de) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Neue heilmittel mit verwendung eines beta3-antagonisten
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2006132196A1 (ja) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
ZA200802811B (en) * 2005-09-02 2009-09-30 Theravida Inc Therapy for the treatment of disease

Also Published As

Publication number Publication date
CN103142586A (zh) 2013-06-12
ES2365161T3 (es) 2011-09-23
AU2006284940B2 (en) 2012-03-22
ZA200802811B (en) 2009-09-30
AU2006284940A1 (en) 2007-03-08
CA2619565C (en) 2015-06-23
NZ565840A (en) 2011-07-29
RU2008112687A (ru) 2009-10-10
CA2619565A1 (en) 2007-03-08
DK1933833T3 (da) 2011-07-25
CN101287462A (zh) 2008-10-15
US20090275629A1 (en) 2009-11-05
BRPI0615432A2 (pt) 2011-05-17
US20100137392A1 (en) 2010-06-03
US7678821B2 (en) 2010-03-16
EP1933833B1 (de) 2011-04-20
US20100152263A1 (en) 2010-06-17
KR101054248B1 (ko) 2011-08-08
US7666894B2 (en) 2010-02-23
EP1933833B8 (de) 2011-09-14
RU2435610C2 (ru) 2011-12-10
US20070053995A1 (en) 2007-03-08
PT1933833E (pt) 2011-07-08
DE602006021444D1 (de) 2011-06-01
IL189546A0 (en) 2008-08-07
US20090318522A1 (en) 2009-12-24
KR20080059155A (ko) 2008-06-26
US7781472B2 (en) 2010-08-24
JP5312027B2 (ja) 2013-10-09
EP1933833A1 (de) 2008-06-25
WO2007027675A1 (en) 2007-03-08
US20130289087A1 (en) 2013-10-31
IL189546A (en) 2014-08-31
US8470864B2 (en) 2013-06-25
JP2009507021A (ja) 2009-02-19
PL1933833T3 (pl) 2011-09-30

Similar Documents

Publication Publication Date Title
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
DE14163637T1 (de) Transdermales therapeutisches System, Rivastigmin enthaltend
NO20063716L (no) Anvendelse av lavdose erytropoietin ved stimulering av endotel forloperceller, regenerering av organer og sinking av progresjonen av sluttorganskader
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200971053A1 (ru) Способы лечения кожных язв
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
DE50211566D1 (de) Kombination ausgewählter opioide mit muscarin-antagonisten zur therapie der harninkontinenz
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
MX2012001708A (es) Anticuerpo humanizado anti-oligomero de amiloide b.
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
EA201270298A1 (ru) Способ лечения злокачественной опухоли
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
RU2013149635A (ru) Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1933833

Country of ref document: EP